Your browser doesn't support javascript.
loading
Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and Treatment of Cancer 90101 CREATE): a multicentre, single-drug, prospective, non-randomised phase 2 trial.
Schöffski, Patrick; Sufliarsky, Jozef; Gelderblom, Hans; Blay, Jean-Yves; Strauss, Sandra J; Stacchiotti, Silvia; Rutkowski, Piotr; Lindner, Lars H; Leahy, Michael G; Italiano, Antoine; Isambert, Nicolas; Debiec-Rychter, Maria; Sciot, Raf; Van Cann, Thomas; Marréaud, Sandrine; Nzokirantevye, Axelle; Collette, Sandra; Wozniak, Agnieszka.
Afiliación
  • Schöffski P; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium. Electronic address: patrick.schoffski@uzleuven.be.
  • Sufliarsky J; National Cancer Institute, Bratislava, Slovakia.
  • Gelderblom H; Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
  • Blay JY; Department of Medical Oncology, Centre Léon Bérard/Université Claude Bernard Lyon Institute, Lyon, France.
  • Strauss SJ; Department of Oncology, University College London Hospitals NHS Trust, London, UK.
  • Stacchiotti S; Department of Medical Oncology, IRCCS Fondazione Istituto Nazionale Tumori, Milano, Italy.
  • Rutkowski P; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute-Oncology Center, Warsaw, Poland.
  • Lindner LH; Klinikum der Universität München, Medizinische Klinik III, Campus Grosshadern, Munich, Germany.
  • Leahy MG; The Christie NHS Foundation Trust, Manchester, UK.
  • Italiano A; Sarcoma Unit, Institut Bergonié, Bordeaux, France.
  • Isambert N; Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
  • Debiec-Rychter M; Department of Human Genetics, KU Leuven, Leuven, Belgium.
  • Sciot R; Department of Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium.
  • Van Cann T; Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals Leuven, Leuven, Belgium; Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
  • Marréaud S; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Nzokirantevye A; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Collette S; European Organisation for Research and Treatment of Cancer, Brussels, Belgium.
  • Wozniak A; Laboratory of Experimental Oncology, Department of Oncology, KU Leuven, Leuven, Belgium.
Lancet Respir Med ; 6(6): 431-441, 2018 06.
Article en En | MEDLINE | ID: mdl-29669701
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Miofibroma / Crizotinib / Quinasa de Linfoma Anaplásico / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Respir Med Año: 2018 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Miofibroma / Crizotinib / Quinasa de Linfoma Anaplásico / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Observational_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Lancet Respir Med Año: 2018 Tipo del documento: Article